In solid organ transplant recipients (sOTRs), 5 years after transplantation cancer is a relevant cause of death. We aimed to report cancer incidence in the Swiss Transplant Cohort Study (STCS) between 2008 and 2014 and conducted a prospective cohort study of kidney, heart, lung, pancreas and liver transplant recipients enrolled into the STCS by retrospective analysis of collected data. The STCS provided data on 2758 solid organ transplants. In total, 134 cases of cancer were observed (30 liver, 21 prostate, 18 lung, 13 kidney, 52 other cancers). Standardised incidence ratios (SIRs) were highest for liver cancer, kidney cancer, thyroid cancer, gastric cancer, bladder cancer, cancer of the oral cavity and the pharynx and for lung cancer. Cancer occurrence differed according to the transplanted organ. Cancers were mainly diagnosed at World Health Organisation (WHO) stages I and IV. Treatment received was mainly surgery and, in some cases, included also radiation and/or chemotherapy. Bladder, kidney, liver, lung and prostate cancer were detected at a younger age compared with the general population. Cumulative hazards for death were increased for transplant recipients with cancer. Solid organ transplant recipients show an organ specific increase of cancer compared with the general Swiss population.
Introduction
There is a large body of evidence indicating that 4 to 5% of solid organ transplant recipients (sOTRs) develop a malignancy after transplantation [1] , which corresponds to an approximately two-to four-fold elevated risk compared to the general population [2] [3] [4] [5] . According to a US study, the risk for malignancies is elevated for 32 different cancer types, with the highest risk for non-Hodgkin's lymAuthor contributions EL was involved in concept, design, data collection, data analysis and interpretation, writing of the article. GH contributed to concept, design, data analysis and interpretation, writing of the article. SS performed data analysis and statistics. AZ, ES, KZ, MS, NS and JS contributed to data collection and critical revision of the article. phoma, lung cancer, liver cancer and kidney cancer [2] . The risk for infection-related malignancies (such as liver cancer) is generally higher than for non-infection-related malignancies; however, some non-infection-related malignancies, such as lip cancer, kidney cancer, thyroid cancer and others, are also more common in sOTRs than in the general population [2] [6] . Squamous cancer of the lip, non-Hodgkin's lymphoma, kidney and bladder cancer are the most reported cancer types in kidney transplant recipients [4] [7] . In heart transplant recipients, the risk is most elevated for non-Hodgkin's lymphoma, oral cancer (comprising cancers of the oral cavity, oropharynx and lips) and lung cancer [8] . An Australian study associated lung transplantation with an increased risk for non-Hodgkin's lymphoma, Merkel cell carcinoma and cancers of the vulva, lip, lung and colorectum. The same study showed an elevated risk for non-Hodgkin's lymphoma, Kaposi sarcoma, colorectal cancer and lip cancer after liver transplantation [4] .
The STCS aims at a comprehensive and structured data collection for all solid organ transplant recipients in Switzerland since May 2008 [9] . Our objective is to report the aggregated results of solid cancer cases occurring in this Swiss Transplant cohort. With the hypothesis of increased cancer incidence, we compare their incidence to the general population and report on treatment and outcome.
Methods

Swiss transplant registry and collection of data
The STCS collects data from all six transplantation centres in Switzerland and started enrolment of patients in May 2008. Patients' base-line data are collected at the time of transplantation and the transplantation centres provide follow-up data on recipients' vital status, health issues and graft function 6 and 12 months after transplantation, followed by yearly follow-ups. There was no specific screening procedure beyond the public screening programmes. Once a cancer became apparent in clinical follow-up, this date was entered into the data base. Each cancer was checked for histological findings to differentiate between primary and metastatic cancers. A detailed description of the design and methodology of the STCS is provided by Koller et al. [10] .
For our report, the following inclusion criteria were applied: all kidney, liver, heart, lung, pancreas, islet cell and small bowel transplant recipients who were included in the 
Statistical analysis
For patients with multiple cancers, each cancer was treated as a separate event for the statistical analysis. The expected number of cancer cases in the SCTS was calculated as the NICER Swiss cancer rate multiplied by observation time in the STCS. Relative risks of cancer in transplant recipients compared to the general population were expressed as standardised incidence ratios (SIRs) per 100,000 personyears, i.e., observed/expected cases. The SIRs were calculated indirectly with the Swiss general population as reference population. Further, there was no stratification of our population. Exact confidence intervals and p-values were calculated based on the Byar formula [12] often applied in similar studies [2] .
We also calculated the median age at cancer diagnosis with interquartile range (IQR), as well as the time from trans-plantation to first cancer occurrence with IQR. We applied the Wilcoxon signed rank test to check for any difference in median age at cancer detection in transplant recipients compared with the general Swiss population with the respective cancer type. The cumulative hazard function was used to find any difference for the cumulative hazards for death in transplant recipients with cancer compared with those without cancer as described by Cleves et al. [13] . If patients developed multiple cancers, the time of the first cancer incidence was used to calculate the cumulative hazards for death.
Results
The characteristics of our patient cohort are shown in table 1. Between May 2008 and September 2014, the STCS included 2758 patients with a solid organ transplant, with a median follow-up of 3 years, yielding 8563 person-years. They received 1557 (56.5%) kidney transplants, 557 (20.2%) liver transplants, 278 (10.1%) lung transplants, 208 (7.5%) heart transplants and 158 (5.7%) other or combined transplants (i.e., single pancreas, small bowel, islet cells or combined, e.g. kidney-lung). The majority of transplant recipients were male (63.9%). As shown in table 2, the infection rates for hepatitis B virus (HBV) and hepatitis C virus (HCV) were reported to be higher for liver transplant recipients, as HBV and HCV often lead to liver cirrhosis and therefore to liver transplantation. The number of malignancies before STCS inclusion was also higher in patients with liver transplant, since previous liver cancer made the patients eligible for a liver transplant. Most transplant recipients were treated with an immunosuppressive regimen comprising calcineurin inhibitors (95.5%) and mycophenolate mofetil (90.7%).
All post-transplant cancer findings (141 patients) registered in the STCS data base were verified by reviewing the patient files in the respective hospitals. Eighteen patients were excluded. In 13 patients, each with one cancer, cancer diagnosis could not be validated (e.g., a benign tumour was registered as cancer or the cancer occurred before transplantation). In another five patients, the transplant was before May 2008 and thus did not meet inclusion criteria. No patient had to be excluded because of insufficient data. In the remaining 123 patients, a total of 134 malignancies were noted (66 malignancies in kidney transplant re- IQR = interquartile range There were 8 patients with both primary non-function and graft loss for different organ transplants. The baseline for immunosuppressive medication was defined as medication start within 7 days before and 7 days after transplantation. Other transplanted organs included multiple transplantations of different organs, single pancreas, small bowel or islet cells transplantation. cipients, 53 in liver, 7 in lung, 6 in heart and 2 in combined transplant patients) (table 3) . High numbers were found for liver cancer in liver transplant recipients (n = 29, a total of 30 liver cancers), of whom 27 patients had liver malignancy before transplantation. In kidney transplant recipients, high numbers of prostate (n = 18), kidney (n = 13), lung (n = 8), bladder (n = 5) and thyroid cancers (n = 5) were noted. In total, in 4.5% of all transplant recipients included in our analysis cancer was observed, and the incidence was especially high in liver transplant recipients (8.8%).
The cancer incidence within the STCS was compared with the general Swiss population by calculation of the SIR. For kidney transplant recipients, an elevated SIR was found for kidney, thyroid, brain, bladder and prostate cancer. In liver transplant recipients, higher incidences were reported for liver, oral cavity and pharyngeal, pancreas, gastric and lung cancer (table 4 ). In the remaining transplant recipients, a higher risk for lung cancer in lung transplant recipients and for testicular cancer in heart transplant recipients was detected.
In our analysis of the median age at cancer diagnosis, we detected an earlier occurrence of bladder, kidney, liver, lung and prostate cancer. For the other cancer types, no difference was detected ( fig. 1 ).
As shown in table 5, most cancer cases were diagnosed at either WHO stage IV (n = 56) or stage I (n = 40). More specifically, of 30 liver cancers, 25 were WHO stage IV at the time of diagnosis. Kidney cancers were more likely to be diagnosed at earlier stages as 13 out of 14 kidney cancers were registered at WHO stage I.
Patients' files were searched to capture all treatments patients received related to their cancers. The treatments are reported in table 6, according to affected organ and histological subtype. Treatment was grouped for patients who received surgery (total n = 73), chemotherapy (total n = 22), radiotherapy (total n = 24) and other therapies (total n = 126), such as transurethral resection of the prostate or hormonal therapy. Figure 2 shows the cumulative hazards for death within the STCS for transplant recipients with cancer compared to those without cancer. The hazards for death in the population with cancer increase early after transplantation and become less common after 2 years of follow-up, whereas for the population without cancer the hazards for death increases only slowly over time.
Discussion
In this first analysis of the Swiss Transplant Cohort Study, we found 134 cancers, corresponding to 4.5% of all transplant recipients, with a median follow-up time of 3 years. An increased risk was seen for a wide range of malignancies.
Our patients showed characteristics similar to populations in similar studies. years) [2, 14] . Our population included a small proportion of patients with re-transplants, who have less exposure to immunosuppression than patients with previous transplants. Our follow-up time was relatively short compared Endocrine system n.a. n.a. n.a. n.a. n.a. n.a.
Vascular system n.a. n.a. n.a. n.a. n.a. n.a.
Unknown primary n.a. n.a. n.a. n.a. n.a. n.a. CI = confidence interval; n.a. = not applicable; SIR = standardised incidence ratio Other transplanted organs included multiple transplantations of different organs, single pancreas, small bowel or islet cells transplantations. "-" means that there were no cancer cases. Significantly different SIR are printed in bold type. "n.a." means that there was no data for the general population available and thus no SIR could be calculated.. [20, 21] . Increased liver cancer risk in liver transplant recipients is probably mainly due to two factors. Firstly, liver transplantion is a common treatment for hepatocellular cancer, with the risk for residual cancer after the initial treatment. Thus, the post-transplant liver cancers are not de novo but rather relapses of pre-existing cancers. The second reason might be the high prevalence of carcinogenic infections such as HBV or HCV. Frequently these infections drove the initial liver cancer that needed liver transplantation in first place [2] . For therapies multiple options were possible. Some cancers were treated with multiple modalities.
In general, the most cited reason for the increased cancer risk in sOTRs is prolonged immunosuppressive therapy. Long-term immunosuppression increases the risk of oncovirally driven malignancies substantially [7] . A second important mechanism is the nonspecific mode of action of most immunosuppressive agents leading to impaired tumour immunosurveillance. Third, some immunosuppressive drugs have pro-oncogenic properties themselves in addition to their immunosuppressive properties. It has been shown that calcineurin inhibitors such as ciclosporin, and to a lesser extent azathioprine and prednisolone, cause a significant impairment of DNA repair mechanisms or drive cancer formation directly, leading to elevated cancer risk in sOTRs [2] [22] [23] . Additionally, ciclosporin is linked to promoting angiogenesis and invasiveness of non-transformed cells in vitro by inducing transcription and expression of the TGF-β1 gene [7] [8].
Hoshida et al. described earlier cancer development in their kidney transplant recipients. The median age of all their cancer patients was 40.0 years, whereas for renal and bladder cancer it was 41.0 years and 43.5 years, respectively. This corresponds to a clearly younger age at cancer development compared with the general population in Japan (64 years) [18] . This study analysed only kidney transplant recipients, but their findings conform to our results on the subgroup of kidney transplant recipients in the STCS.
Cancer stages at diagnosis for lung cancer were comparable to the data for the general Swiss population. According to the Surveillance, Epidemiology, and End Results Program (SEER) database, lung cancers are most often detected in WHO stage IV (57%) and less often in regional (22%) or localised (16%) stages [24] . Liver cancers are commonly found in a localised stage (44%) and less frequently in regional (27%) or metastasised (18%) stages [25] . Our high proportion of WHO stage IV at diagnosis for liver cancer is probably caused by the high prevalence of liver cancer in liver transplant recipients before transplantation. Kidney cancers are mostly diagnosed at localised stages (65%) and less so at regional (16%) or metastasised stages (16%), whereas in our population the cancers were almost exclusively found in WHO stage I, potentially related to closer follow-up in kidney transplant recipients [26] . For prostate cancer, our findings are comparable to the findings of Rohrmann et al., who reported cancer detection mostly in stage I (38.4%) and stage II (22.7%) and less often in stage III (13.1%) and stage IV (10.8%) [27] . In summary, cancer stage at diagnosis for prostate and lung cancer were comparable to the general Swiss population, whereas liver and kidney cancers showed a different pattern.
We found that kidney cancers in the STCS cohort received surgical treatment only, potentially because of rather limited disease. For other common cancer types, such as liver, lung and prostate cancer, the treatment often included serial and multi-modal therapies, as would be expected for these kinds of cancer. Zhou et al. described a 5-year overall mortality of 30.4% for liver recipients with de novo malignancies after transplantation and 31.4% mortality for liver recipients without malignancy [28] . The higher mortality for sOTRs without cancer does not support our findings of an increased cumulative hazard of death for sOTRs with cancer. We observed a higher incidence of all-cause death for sOTRs with cancer in the first 2 years compared with later years after transplantation. We speculate that by the onset of immunosuppression at transplantation, the natural course of disease for cancer would be accelerated. Thus, patients with incipient and as yet undiagnosed cancer at transplantation would fare worse under immunosuppression, contributing to all-cause death in the first 2 years more than in later years.
Although our study gives an overview of the cancer risk in sOTRs, it is limited by the relatively small population size and therefore small number of incident cancers, which
does not yet allow any detailed analysis owing to the limited follow-up time, as cancer incidence probably increases with prolonged immunosuppressive treatment. As the STCS as a prospective cohort will continue to collect data, later studies will provide longer-term data. Also, some patients had prior transplantations in some of which different organs were transplanted. These patients had been exposed to potentially cancer-inducing risk (immunosuppression) prior to inclusion in our study. Because there were only a few patients with prior transplantations, we did not calculate the SIRs for them separately. Additionally, there was no uniform protocol for cancer screening prior to transplantation across all centres, which may have led to an overestimation of cancer incidence. Further limitations include potential divergences between cancer at diagnosis and staging, as full staging was only performed several weeks or months after cancer diagnosis, which may cause an overestimation of initial cancer stages. For the evaluation of cancer treatment, we searched patient files outside of the structured cohort data that are prospectively gathered. Therapies may not all have been registered for patient charts outside the cohort; this may have caused an underestimation of cancer treatments.
The strengths of our study include the inclusion of all sOTRs in Switzerland during the study period, as every transplantation centre in Switzerland has to provide minimum data to the STCS. Even patients moving within Switzerland were usually not lost to follow-up as they continued to be monitored by a different transplantation centre that is an active member of the STCS. Also, the relatively limited number of cancers allowed us to double-check all the findings by source verification in patient files. Therefore, incorrectly entered malignancies could be eliminated for our analysis.
In conclusion, we were able to give an overview of the cancer risk in Swiss sOTRs, who are susceptible to a wide range of cancer types. Depending on the transplant, sOTRs were at increased risk for different cancers. Kidney transplant recipients were at an increased risk for renal cell carcinoma, and prostate, bladder, thyroid and brain cancer; liver transplant recipients were more likely to develop hepatocellular carcinomas, gastric, pancreas and lung cancers, and cancer of the oral cavity and pharynx. For lung transplant recipients we observed an increased risk of lung cancer, whereas in heart transplant recipients risk was increased for cancer of the testis. Building on the results of our study, with a short follow-up but a reliable cohort, extended studies will help to improve cancer surveillance and prevention strategies in sOTRs.
